{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T13:53:17Z","timestamp":1775742797703,"version":"3.50.1"},"reference-count":35,"publisher":"Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Infect Dis"],"published-print":{"date-parts":[[2023,5,31]]},"DOI":"10.7883\/yoken.jjid.2022.532","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T22:10:29Z","timestamp":1672179029000},"page":"167-173","source":"Crossref","is-referenced-by-count":4,"title":["Surveillance of the Antimicrobial Susceptibility and Molecular Characteristics of &lt;i&gt;Neisseria gonorrhoeae&lt;\/i&gt; Isolates Collected in Changsha, China from 2016 to 2021"],"prefix":"10.7883","volume":"76","author":[{"given":"Qianqin","family":"Yuan","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, the Second Xiangya Hospital of Central South University, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiya","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, the Second Xiangya Hospital of Central South University, China"},{"name":"Department of Laboratory Medicine, West China Hospital, Sichuan University, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufeng","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, the Second Xiangya Hospital of Central South University, China"},{"name":"National Clinical Research Center for Metabolic Disease, Key Laboratory of Diabetes Immunology, Ministry of Education, and Department of Metabolism &amp; Endocrinology, the Second Xiangya Hospital of Central South University, China"},{"name":"Department of Laboratory Medicine, First Medical Center of Chinese PLA General Hospital, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengjie","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, the Second Xiangya Hospital of Central South University, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, the Second Xiangya Hospital of Central South University, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danning","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, the Second Xiangya Hospital of Central South University, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinglin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, the Second Xiangya Hospital of Central South University, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanhao","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, the Second Xiangya Hospital of Central South University, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinwu","family":"Guo","sequence":"additional","affiliation":[{"name":"Sansure Biotech Inc., China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongzhi","family":"Chen","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Metabolic Disease, Key Laboratory of Diabetes Immunology, Ministry of Education, and Department of Metabolism &amp; Endocrinology, the Second Xiangya Hospital of Central South University, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingli","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, the Second Xiangya Hospital of Central South University, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4631","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Rowley J, Vander Hoorn S, Korenromp E, et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ. 2019;97:548-562P.","DOI":"10.2471\/BLT.18.228486"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Jarvis GA, Chang TL. Modulation of HIV transmission by <i>Neisseria gonorrhoeae<\/i>: molecular and immunological aspects. Curr HIV Res. 2012;10:211-217.","DOI":"10.2174\/157016212800618138"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Unemo M, Golparian D, Hestner A. Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro Surveill. 2011;16:19792.","DOI":"10.2807\/ese.16.06.19792-en"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Poncin T, Fouere S, Braille A, et al. Multidrug-resistant <i>Neisseria gonorrhoeae<\/i> failing treatment with ceftriaxone and doxycycline in France, November 2017. Euro Surveill. 2018;23:1800264.","DOI":"10.2807\/1560-7917.ES.2018.23.21.1800264"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Y Chen M, Stevens K, Tideman R, et al. Failure of 500 mg of ceftriaxone to eradicate pharyngeal gonorrhoea, Australia. J Antimicrob Chemother. 2013;68:1445-1447.","DOI":"10.1093\/jac\/dkt017"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Lahra MM, Martin I, Demczuk W, et al. Cooperative recognition of internationally disseminated ceftriaxone-resistant <i>Neisseria gonorrhoeae<\/i> strain. Emerg Infect Dis. 2018;24:735-740.","DOI":"10.3201\/eid2404.171873"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Katz AR. Ceftriaxone-resistant <i>Neisseria gonorrhoeae<\/i>, Canada, 2017. Emerg Infect Dis. 2018;24:608.","DOI":"10.3201\/eid2403.171892"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Golparian D, Rose L, Lynam A, et al. Multidrug-resistant <i>Neisseria gonorrhoeae<\/i> isolate, belonging to the internationally spreading Japanese FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, Ireland, August 2018. Euro surveill. 2018;23:1800617.","DOI":"10.2807\/1560-7917.ES.2018.23.47.1800617"},{"key":"9","unstructured":"9. World Health Organization (WHO). WHO guidelines for the treatment of <i>Neisseria gonorrhoeae<\/i>. Available at &lt;https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK379221\/&gt;. Accessed January 17, 2023."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Fifer H, Natarajan U, Jones L, et al. Failure of dual antimicrobial therapy in treatment of Gonorrhea. N Engl J Med. 2016;374:2504-2506.","DOI":"10.1056\/NEJMc1512757"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Eyre DW, Sanderson ND, Lord E, et al. Gonorrhoea treatment failure caused by a <i>Neisseria gonorrhoeae<\/i> strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018. Euro Surveill. 2018;23: 1800323.","DOI":"10.2807\/1560-7917.ES.2018.23.27.1800323"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Yin YP, Han Y, Dai XQ, et al. Susceptibility of <i>Neisseria gonorrhoeae<\/i> to azithromycin and ceftriaxone in China: a retrospective study of national surveillance data from 2013 to 2016. PLoS Med. 2018;15:e1002499.","DOI":"10.1371\/journal.pmed.1002499"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Chen SC, Yin YP, Dai XQ, et al. First nationwide study regarding ceftriaxone resistance and molecular epidemiology of <i>Neisseria gonorrhoeae<\/i> in China. J Antimicrob Chemother. 2016;71:92-99.","DOI":"10.1093\/jac\/dkv321"},{"key":"14","unstructured":"14. Clinical Laboratories Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard; 9th edition. Document M07-A9. Wayne, PA: CLSI; 2012."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Peng JP, Yin YP, Chen SC, et al. A whole-genome sequencing analysis of <i>Neisseria gonorrhoeae<\/i> isolates in China: an pbservational study. EClinicalMedicine. 2019;7:47-54.","DOI":"10.1016\/j.eclinm.2019.01.010"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Liao M, Gu WM, Yang Y, et al. Analysis of mutations in multiple loci of <i>Neisseria gonorrhoeae<\/i> isolates reveals effects of PIB, PBP2 and MtrR on reduced susceptibility to ceftriaxone. J Antimicrob Chemother. 2011;66:1016-1023.","DOI":"10.1093\/jac\/dkr021"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Zhu B, Hu Y, Zhou X, et al. Retrospective analysis of drug sensitivity of <i>Neisseria gonorrhoeae<\/i> in teaching hospitals of South China. Infect Drug Resist. 2021;14:2087-2090.","DOI":"10.2147\/IDR.S317032"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Zheng Z, Liu L, Shen X, et al. Antimicrobial resistance and molecular characteristics among <i>Neisseria gonorrhoeae<\/i> clinical isolates in a Chinese tertiary hospital. Infect Drug Resist. 2019;12:3301-3309.","DOI":"10.2147\/IDR.S221109"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Qin X, Zhao Y, Chen W, et al. Changing of antibiotic susceptibility and molecular characterization of <i>Neisseria gonorrhoeae<\/i> isolates in Guangdong, China: in a background of rapidly raising epidemic. Int J Antimicrob Agents. 2019;54:757-765.","DOI":"10.1016\/j.ijantimicag.2019.08.015"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Zhao L, Liu A, Li R, et al. Trends in antimicrobial resistance in <i>Neisseria gonorrhoeae<\/i> and molecular characteristics of <i>Neisseria gonorrhoeae<\/i> with decreased susceptibility to ceftriaxone in Shandong, China, 2007 to 2014. Int J Antimicrob Agents. 2018;51:52-56.","DOI":"10.1016\/j.ijantimicag.2017.06.004"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Peng T, Lin H, Liu Q, et al. Ceftriaxone susceptibility and molecular characteristics of <i>Neisseria gonorrhoeae<\/i> isolates in Changsha, China. J Infect Chemother. 2017;23:385-389.","DOI":"10.1016\/j.jiac.2017.03.007"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Yan J, Xue J, Chen Y, et al. Increasing prevalence of <i>Neisseria gonorrhoeae<\/i> with decreased susceptibility to ceftriaxone and resistance to azithromycin in Hangzhou, China (2015\u201317). J Antimicrob Chemother. 2019;74:29-37.","DOI":"10.1093\/jac\/dky412"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Merrick R, Cole M, Pitt R, et al. Antimicrobial-resistant gonorrhoea: the national public health response, England, 2013 to 2020. Euro surveill. 2022;27:2200057.","DOI":"10.2807\/1560-7917.ES.2022.27.40.2200057"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Visser M, G\u00f6tz HM, van Dam AP, et al. Trends and regional variations of gonococcal antimicrobial resistance in the Netherlands, 2013 to 2019. Euro surveill. 2022;27:2200081.","DOI":"10.2807\/1560-7917.ES.2022.27.34.2200081"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Unemo M, Ross J, Serwin AB, et al. 2020 European guideline for the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS. 2020:956462420949126.","DOI":"10.1177\/0956462420949126"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Fifer H, Saunders J, Soni S, et al. 2018 UK national guideline for the management of infection with <i>Neisseria gonorrhoeae<\/i>. Int J STD AIDS. 2020;31:4-15.","DOI":"10.1177\/0956462419886775"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. St Cyr S, Barbee L, Workowski KA, et al. Update to CDC&apos;s treatment guidelines for gonococcal infection, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1911-1916.","DOI":"10.15585\/mmwr.mm6950a6"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Nakayama S, Shimuta K, Furubayashi K, et al. New ceftriaxone- and multidrug-resistant <i>Neisseria gonorrhoeae<\/i> strain with a novel mosaic <i>penA<\/i> gene isolated in Japan. Antimicrob Agents Chemother. 2016;60:4339-4341.","DOI":"10.1128\/AAC.00504-16"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Yuan Q, Li Y, Xiu L, et al. Identification of multidrug-resistant <i>Neisseria gonorrhoeae<\/i> isolates with combined resistance to both ceftriaxone and azithromycin, China, 2017\u20132018. Emerg Microbes Infect. 2019;8:1546-1549.","DOI":"10.1080\/22221751.2019.1681242"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Lebedzeu F, Golparian D, Titov L, et al. Antimicrobial susceptibility\/resistance and NG-MAST characterisation of <i>Neisseria gonorrhoeae<\/i> in Belarus, Eastern Europe, 2010\u20132013.<b> <\/b>BMC Infect Dis. 2015;15:29.","DOI":"10.1186\/s12879-015-0755-9"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Gianecini RA, Golparian D, Zittermann S, et al. Genome-based epidemiology and antimicrobial resistance determinants of <i>Neisseria gonorrhoeae<\/i> isolates with decreased susceptibility and resistance to extended-spectrum cephalosporins in Argentina in 2011\u201316. J Antimicrob Chemother. 2019;74:1551-1559.","DOI":"10.1093\/jac\/dkz054"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Harris SR, Cole MJ, Spiteri G, et al. Public health surveillance of multidrug-resistant clones of <i>Neisseria gonorrhoeae<\/i> in Europe: a genomic survey. Lancet Infect Dis. 2018;18:758-768.","DOI":"10.1016\/S1473-3099(18)30225-1"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Lindberg R, Fredlund H, Nicholas R, et al. <i>Neisseria gonorrhoeae <\/i>isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in <i>penA<\/i>, <i>mtrR<\/i>, <i>porB1b<\/i>, and <i>ponA<\/i>. Antimicrob Agents Chemother. 2007;51:2117-2122.","DOI":"10.1128\/AAC.01604-06"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Takahata S, Senju N, Osaki Y, et al. Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of <i>Neisseria gonorrhoeae<\/i>. Antimicrob Agents Chemother. 2006;50:3638-3645.","DOI":"10.1128\/AAC.00626-06"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Golparian D, Hellmark B, Fledlund H, et al. Emergence, spread and characteristics of <i>Neisseria gonorrhoeae<\/i> isolates with in vitro decreased susceptibility and resistance to extended-spectrum cephalosporins in Sweden. Sex Transm Infect. 2010;86:454-460.","DOI":"10.1136\/sti.2010.045377"}],"container-title":["Japanese Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/76\/3\/76_JJID.2022.532\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T05:04:57Z","timestamp":1715317497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/76\/3\/76_JJID.2022.532\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,31]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.7883\/yoken.jjid.2022.532","relation":{},"ISSN":["1344-6304","1884-2836"],"issn-type":[{"value":"1344-6304","type":"print"},{"value":"1884-2836","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,31]]},"article-number":"JJID.2022.532"}}